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A B S T R A C T
Sustained donor engraftment after allogeneic hematopoietic cell transplantation (HCT) converts to healthy donor
hemoglobin synthesis and halts disease symptoms in patients with sickle cell disease and thalassemia major. A disease-
free survival probability that exceeds 90% has been reported when HCT using an HLA-matched sibling donor is
performed in young patients with low-risk disease or treatment-related risk factors. Alternate donor HCT and HCT
in adults is performed infrequently because of a higher risk profile. Transplant-specific risks include conditioning
regimen-related toxicity, graft-versus-host disease, graft rejection with marrow aplasia or disease recurrence, and
infections associated with immunosuppression and delayed immune reconstitution. The magnitude of risk depends
on patient age, clinical status of the underlying disease (eg, organ injury from vasculopathy and iron overload), donor
source, and intensity of the conditioning regimen. These risks are commonly monitored and reported in the short
term. Documenting very late outcomes is important, but these data are rarely reported because of challenges imposed
by patient drop-out and insufficient resources. This report summarizes long-term follow-up results after HCT for
hemoglobin disorders, identifies gaps in knowledge, and discusses opportunities for future investigations. This con-
sensus summary will be followed by a second article detailing comprehensive long-term follow-up recommendations
to aid in maintaining health in these individuals and identifying late complication risks that could facilitate inter-
ventions to improve outcomes.
© 2017 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) for
genetic hemoglobin disorders such as sickle cell disease (SCD)
and thalassemia has curative potential. This is evidenced by
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a cessation of the acute signs and symptoms of the under-
lying disorder after stable engraftment of donor cells. The
assumption that a successful transplant will extend lifes-
pan and stop disease-related complications is central to
decision-making about HCT. The goal of this summary article
is to define and address current gaps in knowledge to create
a roadmap of clinical investigation in this field. In a subse-
quent article we will suggest comprehensive monitoring
guidelines to inform clinical decision-making that might fa-
cilitate health maintenance after HCT for these disorders.
These efforts follow an international working group that con-
vened at the Second Pediatric Blood and Marrow Transplant
International Consensus Conference on Late Effects after HCT
in Minneapolis, Minnesota, USA in May 2016.
CURRENT RESULTS OF HCT FOR HEMOGLOBIN
DISORDERS
Thalassemia
More than 4000 individuals with thalassemia major have
received HCT, with most reports focused on results in chil-
dren and young adults. Risk category assignments have been
developed in several transplant series, determined by recip-
ient age, liver size, liver histology, and whether or not there
is compliance with iron chelation therapy [1-4]. Outcomes
are best in young patients who lack risk factors and receive
HLA-identical sibling HCT. Among 1493 consecutive trans-
plant registry cases reported to the European Group for Blood
and Marrow Transplantation hemoglobinopathy database, the
2-year overall survival (OS) and event-free survival (EFS) rates
were 88% and 81%, respectively. However, among children <
2 years of age who received an HLA-identical sibling al-
lograft, the OS and EFS rates at 2 years were 95% and 93%,
respectively. Conversely, recipients > 18 years of age had OS
and EFS rates of of 80% and 76%, respectively [5]. Results after
HLA-identical sibling umbilical cord blood transplantation are
very similar, with lower rates of acute and chronic graft-
versus-host disease (GVHD) after umbilical cord blood
compared with bone marrow transplantation [6]. Thus, most
clinicians agree that HCT for thalassemia should be consid-
ered in young patients with favorable risk profiles who have
an HLA-identical sibling donor [7].
Sickle Cell Disease
Like thalassemia, HCT for SCD is curative in most indi-
viduals who receive this treatment, but, unlike thalassemia,
HCT is a treatment option that very few families and pa-
tients pursue in the United States [8-11]. The principal reason
for the lower number of SCD transplants is the lack of a suit-
able donor. However, concerns about the toxicity of HCT also
limit its broader application. Among those who have an HLA-
identical sibling donor, results are excellent, and a compilation
of several series showed OS and EFS rates of 95% and 92%,
respectively [12-14]. In addition, reduced-intensity and
nonmyeloablative regimens have been explored as a method
to reduce long-term side effects and mitigate the impact of
vaso-occlusion–induced organ damage on transplant-related
toxicity, particularly in adolescent and adult recipients [15,16].
Results observed after a melphalan/alemtuzumab-based
reduced-intensity conditioning (RIC) regimen applied in chil-
dren and a nonmyeloblative alemtuzumab-based regimen in
adults were similar to results after myeloablative condition-
ing, and EFS rates of 90.7% and 87%, respectively, were
observed. The largest registry series reported to date in-
cluded 1000 recipients with a median age of 9 years treated
between 1986 and 2013 [17]. EFS was lower with increasing
age at transplant (hazard ratio, 1.08; P = .002) and higher if
treated after 2006 (hazard ratio, .94, P = .02). Of interest, 7
of 70 deaths occurred 5 years or longer after HCT, which high-
lights the need for long-term follow-up.
Alternate Donor Transplantation for
Hemoglobin Disorders
Early reports of unrelated donor HCT for thalassemia were
characterized by high rates of graft rejection and transplant-
related mortality, in part related to the older age of recipients,
advanced disease, and unrefined donor selection methods [5].
T cell–depleted haploidentical transplants for thalassemia had
a disease-free survival (DFS) rate of 70% [18]. Registry results
after unrelated umbilical cord blood transplantation for thal-
assemia and SCD were poor, with a DFS rate of 21% in
thalassemia and 50% in SCD recipients [19]. Recent modifi-
cations in donor selection and transplant conditioning have
improved thalassemia-free survival rates during early follow-
up. The addition of hydroxyurea/azathioprine before
conditioning in mismatched and matched related HCT (94%
and 82%, respectively); dexamethasone/fludarabine in advance
of conditioning in haploidentical donor HCT (94%);
fludarabine, thiotepa, and treosulfan in unrelated donor HCT
(82%); and a RIC combination of hydroxyurea, alemtuzumab,
fludarabine, melphalan, and thiotepa (79% and 80% after un-
related donor cord and bone marrow, respectively) together
have improved outcomes [20-24]. Long-term follow-up after
these varied HCT modalities is essential to judge the merits
of alternate donor HCT.
Alternate donor HCT in SCD is less well developed com-
pared with thalassemia. The largest pediatric study in severe
SCD showed 1- and 2-year EFS rates of 76% and 69%, respec-
tively [25]. Complications related to chronic GVHD that
occurred in 38% of recipients, all in the adolescent age group,
resulted in late toxicity after this alemtuzumab/melphalan-
based RIC regimen. In addition, the application of a reduced-
intensity HLA-haploidentical bone marrow transplant in
children with severe SCD demonstrated safety with 97% OS
but 57% DFS due to graft rejection [26]. Clinical trials are un-
derway that aim to reduce HCT-related complications and
increase DFS in both disorders. Again, it is imperative to pair
these short-term aims with long-term healthcare goals as
listed below.
Research Priorities
1. Develop improved alternative donor HCT approaches for
patients who fail standard supportive care (hydroxy-
urea, RBC transfusions, iron chelation therapy).
2. Optimize conditioning regimens for alternate donor HCT
that minimize GVHD risk and reduce long-term conse-
quences of alternate donor HCT.
3. Define the optimal timing and indications for HCT, par-
ticularly with respect to survival outcomes and late effects;
develop HCT pathways for adult patients who are eligi-
ble after optimum supportive care.
ENGRAFTMENT AND CHIMERISM
Thalassemia
Conventional myeloablative conditioning HCT with bu-
sulfan and cyclophosphamide in thalassemia showed a 30%
incidence of mixed hematopoietic chimerism early after HCT,
and those with >25% recipient cells within 2 months were
prone to graft rejection [27]. When reduced-toxicity or RIC
regimens were used, there was an increased incidence of
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mixed chimerism, particularly in those with high-risk thal-
assemia [15,28]. Although the presence of persistent mixed
chimerism can predispose to graft rejection, whole blood
mixed chimerism does not always result in graft loss [29].
In addition, most individuals with mixed chimerism achieve
RBC transfusion independence after HCT and have a clinical
phenotype indistinguishable from full donor engraftment. This
follows the assumption that donor–host chimerism in the
lymphomyeloid lineages does not predict donor erythroid
lineage expansion, which can predominate on the basis of
having a survival advantage compared with recipient thal-
assemic erythrocytes [30,31]. Overall, registry data suggest
that approximately 10% of patients with thalassemia expe-
rience stable mixed chimerism beyond 2 years after HCT with
donor chimerism varying between 15% and 90%. Even when
there are some donor cells in the marrow, stable mixed chi-
merism generally extends transfusion independence in the
long-term and only very rarely progresses to late graft re-
jection [32-34].
Sickle Cell Disease
Persistent mixed chimerism has been observed in 18% to
28% of patients at 24 months after HCT for SCD, where cir-
culating hemoglobin fractions mirror levels in the healthy
donor (sickle trait or HbAA) [10,35]. In 1 case, 11% donor chi-
merism was sufficient for a strong clinical effect. Mixed
chimerism occurred more often after RIC or nonmyeloablative
conditioning (23% and 100%, respectively) and was judged
unstable (with donor T cell chimerism < 50%) in roughly
half the recipients after nonmyeloablative HCT from HLA-
identical siblings [15,16]. In the RIC report of HCT for SCD
(immunoablation with alemtuzumab, fludarabine, and
melphalan), donor chimerism stabilized and immunosup-
pression withdrawal was accomplished in 13 of 15 HCT
recipients. However, the maintenance of mixed chimerism
after minimal-intensity nonmyeloablative conditioning re-
quired extended duration immunosuppression [15,16,36]. The
clinical effect of long-term immunosuppression in this patient
population is not known. As in thalassemia, graft rejection
typically occurs in the first 2 years after HCT, especially if a
progressive decline in donor chimerism is noted early. Moni-
toring the durability and variability of stable mixed chimerism
takes on added importance after gene-inserted or gene-
modified autologous HCT in which the stability of an under-
represented or even rare hematopoietic clone over the long
term is less certain.
Research Priorities
1. Mixed chimerism occurs after myeloablative and reduced-
intensity HCT. Is it stable in the long-term? What are the
effects of extending mixed chimerism by prolonged
immunosuppression?
2. Development of measures that distinguish stable mixed
chimerism versus impending graft rejection (frequency and
sensitivity of testing, lineage tracking, when and if to
intervene)?




Clinical vaso-occlusive painful episodes after HCT for SCD
are eliminated if recipients have sufficient donor erythroid
chimerism to inhibit intracellular sickle polymer formation.
Specifically, acute vaso-occlusive painful episodes, acute chest
syndrome, and similar clinical events are abrogated after HCT.
In addition, reducing the HbS fraction to <30% before trans-
plant as a method to repress an inflammatory milieu that
would otherwise promote cytokine secretion and lympho-
cyte activation has been widely adopted as a supportive care
measure [37]. However, the chronic pain syndrome of SCD
is not immediately halted after successful HCT and can persist
for up to 3 to 6 months or even longer [16]. This observa-
tion supports the notion that not all pain in SCD is vaso-
occlusive in origin. In a series of adults with SCD treated by
nonmyeloablative transplantation that established mixed
donor–host chimerism, a protracted period of pain treat-
ment by opioids was reported. Over time, however, a gradual
taper in the opioid dosing was accomplished, and by 6 months
post-transplant most patients were no longer receiving treat-
ment for chronic pain. This observation suggests that as the
painful stimuli were eliminated after transplant, it was pos-
sible to reset pain threshold levels needed to reduce opioid
therapy. We also speculate that remodeling of previously
activated/dysfunctional vascular/endothelial channels might
occur after HCT to promote cessation of painful stimuli.
Research Priorities
1. How long do pain symptoms persist after successful HCT?
What is the influence of age and pre-existing joint and
bone disease on pain persistence after HCT?
2. Are there biomarkers of pain and vascular dysfunction that




The natural history of sickle lung disease is progressive
restrictive disease that follows recurrent vaso-occlusive events
and loss of functional lung parenchyma. In childhood, there
is also a propensity for asthma and obstructive lung changes.
In most cases serial assessments of lung function after HCT
showed stabilization and, in some cases, improvement in con-
trast to the steady tempo of progression and mortality
predicted by the natural history of this disease [8,9,38].
Because the duration of follow-up study has been short, it
is difficult to predict a long-term trajectory after HCT. Pul-
monary hypertension (defined as a mean pulmonary artery
pressure > 25 mm Hg) is strongly associated with a risk of
sudden death in SCD [39]. Thus, defining the effect of HCT
on this process and on the risk of sudden death in adult re-
cipients is a key research priority. Noninvasive methods of
estimating pulmonary hypertension are controversial;
however, a tricuspid regurgitation jet velocity ≥ 2.5 m/s and
an N-terminal-pro-B-type natriuretic peptide level > 164 pg/
mL or a 6-minute walk distance < 333 m are associated with
a 10-fold increased risk of sudden death. The impact of HCT
on cardiovascular health has not been systematically reported.
Research Priority
1. The cardiopulmonary system is vulnerable to damage in
SCD and thalassemia. What is the long-term outcome of
these systems after transplant, and what role does the age
at transplant play on the reversal of complications such
as cardiac iron overload and pulmonary hypertension?
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GROWTH
Sickle Cell Disease
Growth velocity has been measured after HCT for SCD, and
in general linear growth does not appear to be adversely af-
fected by myeloablative doses of busulfan in the preparative
regimen. Linear growth velocity after HCT was compared with
supportive care alone in the Cooperative Study of Sickle Cell
Disease [40] or by hydroxyurea [41], and transplanted males
had more rapid growth compared to males in the CSSCD
(Table 1). In addition, growth velocities in males and females
treated with hydroxyurea after reaching the maximally tol-
erated dose was not different after HCT. However, recipient
age and stage of pubertal development do influence the effect
of busulfan on growth. Prepubertal children who were near
the onset of the adolescent growth spurt experienced a de-
crease in linear growth velocity after busulfan administration.
In contrast, younger children did not experience decreased
growth during the 2 years after transplantation [42,43].
Thalassemia
Growth delay is common in children with thalassemia due
to iron toxicity and classical iron chelation drugs, particu-
larly in those >7 years of age [44-46]. As many as 55% have
short stature; 27% are severely affected. Growth parameters
can gradually improve after HCT, but this catch-up can be
compromised by toxicities encountered from preparative regi-
mens or post-HCT complications such as GVHD.
Research Priority
1. Because most transplants are performed in children, moni-
toring growth and development is a very high priority.
Which HCT regimens adversely affect growth? What effect
does the underlying disease exert on growth and bone and
joint health?
GONADAL FUNCTION, PUBERTY, AND INFERTILITY
Sickle Cell Disease
Gonadal dysfunction related to the hemoglobinopathy can
predate HCT and is associated with chronic medical thera-
pies, iron deposition, and iron-induced oxidative stress leading
to hypothalamic-pituitary-gonadal dysfunction (most com-
monly hypogonadotropic hypogonadism) in those who are
chronically transfused [47-49]. Other potential contribut-
ing factors for gonadal dysfunction in SCD include priapism,
testicular ischemia/infarction, and the use of hydroxyurea [50].
Although gonadal dysfunction is not universal after HCT for
SCD, it is a significant risk, and most patients who receive a
busulfan-based regimen will be infertile [51-53]. Females are
particularly sensitive to gonadotoxic therapy because of having
a finite reserve of ovarian follicles. Ovarian failure occurs soon
after HCT or manifests longer after HCT as premature meno-
pause. Recipients who are postpubertal who have received
myeloablative conditioning (high-dose busulfan) have a higher
risk of ovarian dysfunction after HCT [43,51,54]. Male recipi-
ents with SCD have low to normal levels of testosterone
accompanied by elevated gonadotropin blood levels after
transplantation, most consistent with hypogonadotropic hy-
pogonadism in pubertal males. Gonadal dysfunction is also
dependent on the intensity and content of the conditioning
regimen. The risk of infertility was 50% and 10% in postpu-
bertal males treated with busulfan/cyclophosphamide and
cyclophosphamide alone, respectively [55]. RIC regimens
appear to have a milder impact on gonadal function [56,57].
Thalassemia
In thalassemia major there is dual toxicity on gonadal func-
tion after HCT caused by iron overload and myeloablative
chemotherapy. The risk of ovarian failure was very high in
girls of pubertal age, approaching 80% to 100% [44,58,59].
Ovarian toxicity was less frequent if HCT was performed
before puberty. Males had a higher tolerance, and those who
were pubertal at the time of HCT had normal testosterone
levels. HCT in the prepubertal period affected puberty and
testosterone levels in 30% to 40% of recipients [59].
Research Priority
1. Gonadal function and fertility pre- and post-HCT are poorly
characterized in large registries. Novel transplant regi-
mens that modify the chemotherapy intensity and reduce
the toxicity profile are under development. However, the
effect of these regimens on gonadal function is not yet
known. It will be very important to collect these data pro-
spectively to better inform families about fertility.
IRON OVERLOAD
Iron accumulation is inevitable as a consequence of chronic
transfusion dependence and contributes to long-term mor-
bidity post-HCT (Figure 1) [60]. Cardiomyopathy from iron
overload in young adulthood remains the leading cause of
mortality in medically treated thalassemia major [61]. After
a successful transplant, iron overload is “frozen” (there is no
additional iron loading and presumably fewer reactive iron
species are generated). However, the acquired iron over-
load can interfere with the delicate intracellular labile iron
balance, thus generating damaging reactive oxygen species.
The persistence of tissue iron overload can exert long-term
risks. The risk of persistent iron overload after HCT has been
demonstrated in prospective studies in which progression of
liver disease to cirrhosis and cardiac abnormalities has been
documented in some patients long after HCT [62,63]. This
implies that any tissue insult should be considered in the long
term (in decades) as a potential cause of morbidity and mor-
tality potentiated by additional comorbidities [63]. Moreover,
other comorbidities or acquired toxic insults that common-
ly present during “normal” life result in some degree of iron
overload as demonstrated by the presence of mild iron over-
load with hepatitis C virus infection. Large epidemiologic
population-based studies and follow-up in patients with he-
moglobinopathies have shown that elevated transferrin
saturation was associated with increased morbidity and mor-
tality, providing further evidence for the need to tackle iron-
related problems after HCT [64]. Endocrine organs affected
by iron overload include hypothyroidism in 10%, parathy-
roid insufficiency, and diabetes mellitus. Toxicity caused by
preparative regimens also can exacerbate endocrine function.
Table 1
Comparison of Height and Weight Velocities in Males and Females after HCT















CSSCD [40] .01 .12 .0004 .08
Hydroxyurea [41] .68 .25 .30 .92
CSSCD indicates Cooperative Study of Sickle Cell Disease.
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For example, alemtuzumab increases the risk of autoim-
mune thyroid disease [57,65].
Sickle Cell Disease
In SCD the interaction of disease pathophysiology and iron
overload appears to modulate iron deposition and tissue injury
to a lesser extent than thalassemia [66]. However, post-
transplant monitoring of iron overload and therapeutic
management still remain applicable in this disorder as in thal-
assemia major.
Research Priorities
1. Study the function of primary organs (brain, heart, lungs,
kidneys) impacted by iron overload before and after HCT.
2. Endocrine organs at risk also require systematic long-
term follow-up to determine the incidence of late effects
on function. Assess interventions (phlebotomy and iron
chelation therapy) to reduce iron burden.
IMPACT OF HCT ON THE CENTRAL NERVOUS SYSTEM
IN SCD
Two of the largest patient series of HLA-identical sibling
HCT in children with SCD in the United States and France
showed that most patients treated by HCT experience sta-
bilization of pre-existing cerebral vascular disease [8,9].
Twenty-nine individuals had a stroke as indication for HCT
in the US multicenter trial (Table 2). In this group 3 partici-
pants had a new stroke after the HCT procedure (1 stroke
occurred after graft rejection) corresponding to a stroke event
rate of 2.8 events per 100 patient years. There were 10 par-
ticipants who had a silent cerebral infarction observed as an
incidental finding before HCT. With a mean of 1.7 years after







































Figure 1. Mechanism of iron-related tissue injury in thalassemia patients. At transferrin saturation levels > 60% to 70%, levels of nontransferrin-bound serum
iron (NTBI) and labile plasma iron (LPI) increase, resulting in iron-related damage to the liver, heart, bone marrow, and bones in situations of chronic iron
overload after chronic transfusion therapy for thalassemia. (Modified from Angelucci and Pilo [60]).
Table 2
Neurologic Outcomes in Surviving Patients Enrolled in the Collaborative Trial (N = 55) [54]






MRI Appearance after HCT (Median Duration, Range in Years after BMT)
“Clinical” stroke, n = 29 (7.0; 3.4-12.4 yr) n = 1 n = 1 (SAH) 27/28 studied had stable or improved MRI; 1 not studied (3.2 yr; .6-7.3)
“Silent” stroke*, n = 10 (6.7; 3.4-10.6 yr) n = 0 n = 0 All 8 studied had stable (n = 4) or improved (n = 4) MRI; 2 not studied (1.7 yr; .6-4.9)
Normal, n = 16† (6.6; 3.1-11.1 yr) n = 0 n = 0 All 10 studied had normal MRI; 6 not studied (3.1 yr; .5-5.2)
CNS indicates central nervous system; BMT, bone marrow transplantation; SAH, subarachnoid hemorrhage; MRI, magnetic resonance imaging.
* “Silent stroke” refers to individuals with silent cerebral infarction.
† Including 4 with no baseline exam.
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new or progressive infarct in these 10 patients. A similar ex-
perience was reported by the French consortium in 87
recipients with SCD. Among 36 children who had a stroke
before HLA-identical sibling HCT, 2 had recurrent strokes. With
a median follow-up of 6 years, the risk of recurrent stroke
in those with stroke as the indication for HCT was ~.93 per
100 patient years. Together, these observations suggest that
HCT is an effective therapy for secondary prevention of strokes
in children with either overt strokes or silent cerebral in-
farcts, but it is not universally protective. However, systematic
long-term follow-up in a larger group of patients is needed
to establish the natural history of cerebrovascular disease after
HCT.
There appears to be a limited period of time after HCT
when ensuring adequate hemostasis by maintaining the plate-
let count > 50,000/mm3 until stable engraftment protects from
intracranial hemorrhage. In addition, there appears to be a
risk during the peritransplant period when the evolution of
brain injury by magnetic resonance imaging can progress
before subsequent stabilization [67]. Finally, strict control of
hypertension, seizure prophylaxis, and avoidance of hypo-
magnesemia are important in preventing posterior reversible
encephalopathy syndrome after HCT for SCD. Even when these
measures are used, posterior reversible encephalopathy syn-
drome and seizures can occur in up to 25% of recipients
[25,68].
Research Priorities
1. Assess the therapeutic effect of HCT for cerebral
vasculopathy stabilization and protection from progres-
sive brain injury.
2. Assess the reversibility of vascular damage after success-
ful HCT by systematic brain imaging, especially in older
recipients with established vascular disease pretransplant.
NEUROCOGNITION AND RELATED FOLLOW-UP
Cognitive deficits that impact educational attainment are
common among children with SCD. Central nervous system
injury is 1 of the greatest risk factors for cognitive deficits
among people with SCD where approximately 40% of chil-
dren will have a silent cerebral infarct [69]. Without treatment,
infarcts are progressive in the form of transient ischemic
attacks, recurrent silent cerebral infarct, or overt stroke. Re-
cently, results from the Silent Infarct Transfusion Trial
supported chronic transfusion as a method to decrease this
risk of recurrence [70]. However, no treatment has been found
to reverse the cognitive deficits, and the cognitive impair-
ments appear to progress over time, with a decrease of one
IQ point each year [71]. Biologic risk factors for cognitive im-
pairments include anemia, decreased oxygen saturation, and
elevated TCD [72]. Children with SCD have lower scores on
measures of intelligence compared with unaffected peers or
siblings. Children with SCD commonly have deficits in cog-
nitive domains, including impairments in processing speed
[73,74], executive function [75], visuomotor functioning [76],
and attention [76]. These cognitive functions carry particu-
lar importance for educational attainment. Over 60% of
children with SCD and silent infarcts had either failed a grade
or received special education services [77]. Educational in-
terventions are typically implemented to address specific
challenges (rather than global impairment) that impact a stu-
dent’s ability to learn.
HCT may ameliorate cognitive decline among children with
SCD. In the only published data of longitudinal cognitive
outcomes of children with SCD and HCT from the French in
a cohort spanning 1992 to 2006, 15 children (mean age, 8.9
years) were evaluated before and 36 and 60 months after
transplantation [78]. Thirteen had an ischemic stroke before
HCT. The median full-scale IQ was 87, 94, and 94 before HCT
and 36 months and 60 months after HCT, respectively. Un-
fortunately, uniform data on a large scale have not been
available or published in the United States. Although some
clinical evaluations are completed before and after HCT, the
same tests were not uniformly used at both time points.
Without the inclusion of cognitive outcomes in HCT re-
search protocols, uniform evaluations will not be used across
centers or may not be completed at all. Given the impor-
tance of cognitive function in adherence to medical treatment
and educational outcomes, cognition needs to be measured
and shared with medical providers, families, and educators
to provide supportive interventions.
Research Priorities
1. Assess in greater detail whether successful HCT stabi-
lizes cognitive function and/or helps improve it.
2. What are the effects of complications such as seizures, pos-
terior reversible encephalopathy syndrome, or GVHD on
neurocognitive functions during follow-up?
IMMUNE RECONSTITUTION
Immune reconstitution typically occurs over the first year
after HCT as immunosuppression is withdrawn after HLA-
identical sibling HCT for hemoglobin disorders [15,79]. Factors
that delay immune reconstitution include cord blood or T cell–
depleted grafts, delayed engraftment, or the use of extended
periods of systemic immunosuppression to treat chronic
GVHD [57,80,81]. Newer approaches such as selective deple-
tion of alloreactive T cells and infusion of T cell lines/clones
specific for life-threatening pathogens may offset GVHD,
prevent infection-related mortality, and allow immune re-
constitution early [82,83]. Response to reimmunization and
the development of protective antibody titers depend on
immune reconstitution. This is of particular importance in
SCD patients who are susceptible to sepsis from encapsu-
lated bacteria in the absence of immune recovery. Protein
conjugates of the pneumococcal vaccine are more potent an-
tigens evoking antibody responses earlier in a recovering
immune system compared with the pneumococcal polysac-
charide vaccine that should be administered subsequently
after the former. Although several transplant studies have de-
scribed immune reconstitution in small numbers of patients,
uniform measurements of immunologic recovery would assess
the tempo of recovery by regimen used, facilitate support-




The spleen is subject to autoinfarction in SCD, and
asplenism occurs in 90% of children with sickle cell anemia
by 5 years of age. Because of the regenerative capacity of the
spleen, recovery of spleen function has been observed after
successful HCT. In a recent, large, multicenter retrospective
analysis, splenic recovery was observed in >90% of recipi-
ents. Splenic recovery beyond 15 years of age is less certain,
and most individuals > 15 year of age treated by regular RBC
transfusions do not recover spleen function [84].
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Thalassemia
The massive splenomegaly associated with hypersplen-
ism in selected thalassemia syndromes traditionally was
treated by splenectomy to reduce the transfusion burden, al-
though this practice has been modified more recently. After
HCT, the asplenic patient should be managed per published
guidelines.
Research Priorities
1. Develop uniformity in assessing immune reconstitution
to be able to compare transplant conditioning regimens.
2. Determine splenic function after HCT, especially the impact
of age at HCT in SCD.
3. Systematically evaluate response to immunization after
transplant as a measure of protection against encapsu-
lated bacteria.
HEALTH-RELATED QUALITY OF LIFE
Thalassemia
Health-related quality of life (HRQoL) measurements in
thalassemia are shown in Table 3. Overall, HCT was associ-
ated with improved health, activity, and emotional well-
being compared with chronic transfusion therapy. These
improvements were not as robust when transplants were per-
formed in older patients with advanced disease or in the
presence of chronic GVHD. The immediate post-HCT period
(the first 3 months) was also associated with impaired phys-
ical function especially in children with no simultaneous
impact noted on emotional and psychosocial domains [85-87].
Sickle Cell Disease
Table 4 summarizes HRQoL reported after HCT for SCD.
Over different assessments there is consensus that HRQoL gen-
erally worsens immediately after HCT but returns to baseline
Table 3
Overview of Studies Evaluating HRQoL in Patients with Thalassemia after HCT
Source Module Number Timing Conclusions








Adults >18 years: Overall health better after HCT—less
medical aids, higher activity, better relationships, and
physical health.
Children <18 years: Better physical function after HCT.
Lower scores on school attendance restriction and
hospital visits.
Caocci et al., 2011 [86] PedsQL™ 4.0 28 Thalassemia HCT
patients
Before HCT, 3, 6,
and 18 months
after HCT
High agreement between child–self and patient–proxy
ratings.
Physical function decline noted until 3 months after HCT
and subsequently increased. No significant difference in
emotional, social, or psychosocial domains.









Higher HRQoL after HCT. Older age and chronic GVHD
affected HRQoL negatively.
WHOQOL-BREF(HK) indicates World Health Organization Quality of Life Measure Abbreviated; PedsQL™4.0, Pediatric Quality of Life Version 4.0; SF-36, Short
Form 36 version 1; FACT-BMT, Functional Assessment of Cancer Therapy—Bone Marrow Transplant.
Table 4
Overview of Studies Evaluating HRQoL in Patients with SCD after HCT
Source Module Number of Patients Assessments Conclusions
Kelly et al., 2012 [88] CHRIs 7 SCD HCT patients
6 Thalassemia HCT patients
Comparison group: children
undergoing HCT for acquired
disorders
Before HCT, day +45,
3, 6 and 12 months
after HCT
Lower physical and emotional function domain
scores for 3 months after HCT and subsequently
returned to pre-HCT baseline.
Bhatia et al., 2014 [13] PedsQL™4.0 17 SCD HCT patients
23 Caregivers for SCD
patients
Before HCT, days +180
and +365 after HCT
At 1 year after HCT, patient and parent proxies
showed improvement in overall, physical, social,
and emotional HRQoL domains.




13 SCD HCT children
21 Caregivers
Before HCT, days +100,
180, and +365 after HCT
At 100 days parents reported significantly
worse self-esteem HRQoL scores but better
general health perception.
At 6 and 12 months after HCT, children and
parents reported significantly improved change
in health scores.
Saraf et al., 2016 [89] SF36 version 1 13 Adult SCD patients Before HCT, Days +30, +90,
and +365 after HCT
One year after HCT, significant improvement in
body pain, general health, and vitality domains
reported. Lower degree of improvement
reported in social and mental health function
domains.
CHRIs indicates Child Health Rating Inventories General Heath and HCT module; CHQ-Parent Form 50, Child Health Questionnaire Form 50; CHQ-Child Form
87, Child Health Questionnaire Form 87.
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thereafter and continues to improve with time, with corre-
lation between patient and parent perceptions. Improvements
were reported in multiple domains including general health,
physical, emotional, and social functions [13,25,88,89].
Research Priorities
1. Does longitudinal tracking of HRQoL after HCT reflect
improvement over supportive treatment for hemoglobin-
opathies? These comparisons will require nontransplanted
control subjects.
2. Define assessment tools that are age appropriate for moni-
toring HRQoL in SCD and thalassemia to capture the QoL
domains.
3. How does HRQoL differ in older patients with advanced
disease after HCT or who develop GVHD? The reversibil-
ity of disease-related sequelae and the variable severity
of GVHD will influence HRQoL.
HEALTHCARE UTILIZATION
The cost of care with regard to the physical, psychoso-
cial, and financial burden of hemoglobin disorders has not
been rigorously studied after HCT.
Sickle Cell Disease
Recent cost estimates range from $150,000 to $250,000
in the first year post-transplant [90] after HCT for SCD. In con-
trast, single-center publications have reported actual total
median costs as high as $451,000 for both inpatient and out-
patient care [91]. Despite this broad range of costs, there is
general agreement that HCT for SCD generates higher medical
and hospitalization costs in the first year after HCT [91-93]
that subsequently decrease over time [88,91,92]. Current es-
timates suggest that HCT for SCD is cost-efficient compared
with standard supportive care with current standard care hy-
droxyurea and/or chronic transfusions representing a
substantial burden to the healthcare system with an esti-
mated $1.6 billion per year [90,91,94,95]. Further analysis of
costs of care for standard treatment including curative thera-
pies will help assess the utility of treatment options.
Thalassemia
Treating thalassemia major, like SCD, is a major healthcare
challenge and a burden on the national healthcare system in
many countries. The Italian Thalassemia Cost & Outcomes
Assessment study reported mean direct societal costs (limited
to transfusions and chelation with deferoxamine and/or
deferiprone) of €1242 per patient per month in 2006 [96]. In
the Italian society with approximately 7000 patients with thal-
assemia major, the annual direct society cost corresponds to
€107 million per year, 56% (€60 million/year) attributed to iron
chelation therapy and 33% (€35 million per year) to transfu-
sions. Deferasirox (Exjade, Novartis Pharmaceuticals Inc., Basel,
Switzerland) is the preferred oral chelator in terms of compli-
ance.However,deferasiroxcosts3timesasmuchasdeferoxamine,
thus increasing the cost further. Studies from Thailand compar-
ing cost-effectiveness of HLA-identical sibling HCT measured
in terms of quality-adjusted life-years gained in children and
young adults with thalassemia compared with conventional
therapy suggest that it is a cost-effective strategy, although the
actualfinancialburdenishigh[97,98].Withimprovementintrans-
plant methods and supportive care, alternate donor transplants
aim to match survival after HLA-identical sibling HCT. Contin-
ued assessment of the cost-effectiveness of HCT especially after
alternate donor transplants will be informative.
Research Priority
1. How does post-transplant healthcare utilization long-
term (>2 years after HCT) compare with disease- and age-
matched nontransplanted control subjects with SCD and
thalassemia?
SUMMARY
Early follow-up after HCT for hemoglobinopathies sug-
gests that the procedure protects and in some cases reverses
disease-related organ damage, which together enhance
HRQoL. As transplant outcomes improve and the toxicity of
the procedure is reduced, the future application of HCT for
hemoglobin disorders will focus on prevention of disease-
related complications and improved quality of life. The
benefits of cure must be balanced with HCT complications
such as GVHD, graft rejection, and transplant-related mor-
bidities in the short and long term. Post-HCT follow-up studies
in hemoglobinopathies and other malignant and nonmalig-
nant disorders have informed us about kidney, cardiovascular,
endocrine, and gonadal sequelae in the long term. Each of
these aspects requires systematic follow-up and interven-
tion to understand and mitigate these events. This report
summarizes current knowledge and highlights gaps in un-
derstanding about late effect of HCT for thalassemia and SCD.
We will use this summary to help guide and develop a com-
prehensive roadmap for future long-term studies after HCT
and other curative therapies.
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